All News

Persistent chemotherapy drug shortages challenge oncology providers. American Oncology Network employs a drug shortage committee for organized shortage management that involves pharmacists and interdisciplinary stakeholders.

As patients take more proactive roles in their health, they may feel too intimidated to discuss herbal medicinal use with their providers or may be unaware of potential interactions with their drug therapies.

The study results also found that exposure to tree canopy area may protect children from asthma development; however, efficacy decreased as weed pollen exposure increased.

Zanubrutinib shows potential in treating patients with treatment-naïve high-risk chronic lymphocytic leukemia and/or small lymphocytic lymphoma with del(17p) and/or TP53 mutation.

Precision medicine takes a proactive stance by leveraging genetic insights to guide treatment decisions from the outset.

OTC products are cost-effective and offer patients a convenient self-treatment option.

Trametinib may become an alternative treatment to hematopoietic stem cell transplantation in patients with relapsed or refractory juvenile myelomonocytic leukemia (JMML).

Brentuximab vedotin in combination with lenalidomide and rituximab had a favorable safety profile for patients with relapsed/refractory diffuse large B-cell lymphoma.

The new findings were presented as an oral presentation at the 2024 European Calcified Tissue Society Congress, held from May 25, 2024, to May 28, 2024.

Researchers are working to solve consistency and ecological and ethical concerns in pharmaceutical formulations

Repotrectinib has also shown significant efficacy in ROS1 fusion-positive non¬–small cell lung cancer (NSCLC), which was also studied in the TRIDENT-1 trial.

This article provides an overview of data supporting the utility of covalent Bruton tyrosine kinase inhibitors in chronic lymphocytic leukemia and details important considerations when choosing among agents.

Amplification of chromosome 1q is associated with poorer treatment outcomes for patients with relapsed/refractory and newly diagnosed multiple myeloma.

The autoinjector will provide another option for adults in addition to the prefilled syringe that is currently available.

Anti-amyloid antibody administration decreased plaque volume in clinical trials of patients with early AD, indicating that passive immunotherapies could be a promising treatment for the disease.

The SCDM model demands more than the traditional roles assigned to pharmacists, requiring an enhanced level of patient engagement, medical knowledge, and legal authority to implement effectively

With the new ruling, announced Thursday, the pills will continue to be able to be mailed to patients without an in-person visit with a physician.1

Listen closely and ask clarifying questions to best address patient challenges.

Incorporating ethical principles at all levels can ensure the best possible outcomes under difficult circumstances.

Reducing sodium intake is associated with decreased risk of atopic dermatitis (AD) and flares.

Eating a poor diet might lead to structural brain changes that cause the development of common mental disorders (CMD).

Tune into this episode of “Public Health Matters” to hear Dr. Bolu Oladini’s unconventional journey within pharmacy, his passion for mental health, and how artificial intelligence is beginning to be integrated into health care and everyday life.

At ASHP Pharmacy Futures 2024, Mei T. Liu, PharmD, BCPP, highlights the global prevalence and multifaceted nature of depression, its bidirectional relationship with medical conditions, and the need for diverse, evidence-based treatment options.

Lindsey P. Sheehan, PharmD, MPA, MBA, discusses ongoing challenges of diagnosing and treating hepatitis C, emphasizing its increased incidence among younger populations and ongoing low rates of diagnosis.

The indication is for the improvement of glycemic control in pediatric patients aged 10 and older with type 2 diabetes and comes after positive results from the phase 3 T2NOW clinical trial.

Continuous glucose monitoring systems offer timely biofeedback for patients with type 2 diabetes.